Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain
Journal of Pain, Volume 2, No. 4, Year 2001
Notification
URL copied to clipboard!
Description
The objective of this international, multicenter, open-label trial was to assess the efficacy and safety of up to 12 months of therapy with transdermal therapeutic system (TTS) fentanyl in patients (n = 532) with chronic noncancer pain. The trial was completed by 301 (57%) of the patients. The main outcome measures were pain control assessment, global treatment satisfaction, patient preference for TTS fentanyl, and quality of life. The mean dose of transdermal fentanyl (TDF) increased from 48 to 90 uμg/h during a period of 12 months. During treatment, on average 67% of patients within the efficacy analysis group (n = 524) reported very good, good, or moderate pain control. Global satisfaction (very good or good) was also stable at 42%. The majority (86%) of patients reported a preference for TDF over their previous treatment (P < .001, binomial test). Short Form 36 quality-of-life scores improved from baseline for bodily pain. The most frequent treatment-related adverse events were nausea (31%), constipation (19%), and somnolence (18%). With regard to opioid-specific adverse events (respiratory depression [less than 1%], adrenal insufficiency [less than 1%], drug abuse/dependence [1%], and opioid withdrawal syndrome [3%]), these were extremely rare and, with the exception of opioid withdrawal syndrome, none was considered definitively related to the treatment. Long-term treatment with TDF provided a stable degree of pain control in the majority of patients with moderate to severe chronic noncancer pain. It was preferred by the majority of patients compared with their previous opioid medication. Overall, long-term treatment with TDF was generally well tolerated, particularly in view of the low incidence of potentially serious side effects such as drug abuse/dependence and respiratory depression. However, at present, it is important that patients receiving TDF should still be subject to careful assessment and monitoring. © 2001 American Pain Society.
Authors & Co-Authors
Milligan, Keith A.
United Kingdom, Middlesbrough
The James Cook University Hospital
Lantéri-Minet, Michel
France, Nice
Centre Hospitalier Universitaire de Nice, Hôpital Pasteur
Borchert, Klaus
Germany, Greifswald
Anästhesiologische Praxis
Helmers, Henk
Netherlands, Amersfoort
Eemland Hospital
Donald, Royden
South Africa, Cape Town
Strand Private Hospital
Kress, Hans Georg
Austria, Vienna
Medizinische Universität Wien
Adriaensen, Hugo F.
Belgium, Edegem
Universitair Ziekenhuis Antwerpen
Moulin, Dwight E.
Canada, London
London Health Sciences Centre
Järvimäki, Voitto
Finland, Oulu
Oulun Yliopisto
Haazen, Ludo
Belgium, Beerse
Janssen Pharmaceutica, Headquarters
Statistics
Citations: 93
Authors: 10
Affiliations: 10
Identifiers
Doi:
10.1054/jpai.2001.25352
Research Areas
Disability
Health System And Policy
Mental Health
Substance Abuse
Study Design
Cohort Study